BACKGROUND: Fibrosis progression in hepatitis C virus (HCV)-infected patients varies greatly between individuals. Chemokines recruit immune cells to the infected liver and may thus play a role in the fibrosis process. AIM: To investigate plasma levels of a diverse chemokine panel in relation to liver fibrosis. METHODS: African-American and Caucasian HCV genotype 1 infected patients were treated with peginterferon (pegIFN) and ribavirin (RBV) for 48 weeks (VIRAHEP-C cohort). Plasma levels of 13 cytokines were studied at baseline (n = 386). Subsequently, GROα levels were assessed in a sub cohort (n = 99) at baseline, and at 4 and 12 weeks after start of pegIFN/RBV treatment. RESULTS: Increased severity of fibrosis (Ishak fibrosis score 0-2 vs. 3-6) was associated with increased plasma IP-10 (CXCL10) and IL-8 (CXCL8) levels, and decreased plasma levels of the chemokine growth-related oncogene (GRO, CXCL1-3). Plasma GRO levels were also positively correlated with platelet counts, and were higher in African-American as compared to Caucasian patients. In response to pegIFN/RBV treatment, GROα levels increased in Caucasian but not African-American patients from week 4 onwards. CONCLUSIONS: The association with severity of fibrosis and platelet count positions plasma GRO as a potential biomarker for liver fibrosis in HCV-infected patients. The secretion of GRO by platelets may explain the correlation between GRO plasma level and platelet count. The ethnic difference in GRO levels both pre-treatment and in response to pegIFN/RBV might be driven by a genetic polymorphism in GROα associated with higher plasma levels and more common in the African-American population.
BACKGROUND:Fibrosis progression in hepatitis C virus (HCV)-infectedpatients varies greatly between individuals. Chemokines recruit immune cells to the infected liver and may thus play a role in the fibrosis process. AIM: To investigate plasma levels of a diverse chemokine panel in relation to liver fibrosis. METHODS: African-American and Caucasian HCV genotype 1 infectedpatients were treated with peginterferon (pegIFN) and ribavirin (RBV) for 48 weeks (VIRAHEP-C cohort). Plasma levels of 13 cytokines were studied at baseline (n = 386). Subsequently, GROα levels were assessed in a sub cohort (n = 99) at baseline, and at 4 and 12 weeks after start of pegIFN/RBV treatment. RESULTS: Increased severity of fibrosis (Ishak fibrosis score 0-2 vs. 3-6) was associated with increased plasma IP-10 (CXCL10) and IL-8 (CXCL8) levels, and decreased plasma levels of the chemokine growth-related oncogene (GRO, CXCL1-3). Plasma GRO levels were also positively correlated with platelet counts, and were higher in African-American as compared to Caucasian patients. In response to pegIFN/RBV treatment, GROα levels increased in Caucasian but not African-American patients from week 4 onwards. CONCLUSIONS: The association with severity of fibrosis and platelet count positions plasma GRO as a potential biomarker for liver fibrosis in HCV-infectedpatients. The secretion of GRO by platelets may explain the correlation between GRO plasma level and platelet count. The ethnic difference in GRO levels both pre-treatment and in response to pegIFN/RBV might be driven by a genetic polymorphism in GROα associated with higher plasma levels and more common in the African-American population.
Authors: Tarik Asselah; Ivan Bièche; Ingrid Laurendeau; Valérie Paradis; Dominique Vidaud; Claude Degott; Michelle Martinot; Pierre Bedossa; Dominique Valla; Michel Vidaud; Patrick Marcellin Journal: Gastroenterology Date: 2005-12 Impact factor: 22.682
Authors: K Ishak; A Baptista; L Bianchi; F Callea; J De Groote; F Gudat; H Denk; V Desmet; G Korb; R N MacSween Journal: J Hepatol Date: 1995-06 Impact factor: 25.083
Authors: Ancha Baranova; Mohammed H Jarrar; Maria Stepanova; Andrew Johnson; Nila Rafiq; Terry Gramlich; Vikas Chandhoke; Zobair M Younossi Journal: Digestion Date: 2010-09-15 Impact factor: 3.216
Authors: Robert J Fontana; David E Kleiner; Richard Bilonick; Norah Terrault; Nezam Afdhal; Steven H Belle; Lennox J Jeffers; Darmendra Ramcharran; Marc G Ghany; Jay H Hoofnagle Journal: Hepatology Date: 2006-10 Impact factor: 17.425
Authors: Marija Zeremski; Lydia M Petrovic; Luis Chiriboga; Queenie B Brown; Herman T Yee; Milan Kinkhabwala; Ira M Jacobson; Rositsa Dimova; Marianthi Markatou; Andrew H Talal Journal: Hepatology Date: 2008-11 Impact factor: 17.425
Authors: Chen Wei Chu; Shinn Jang Hwang; Rei Hwa Lu; Chiung Ru Lai; Jiing Chyuan Luo; Yuan Jen Wang; Full Young Chang; Shou Dong Lee Journal: Hepatol Res Date: 2002-11 Impact factor: 4.288
Authors: Jan Korbecki; Iwona Szatkowska; Patrycja Kupnicka; Wojciech Żwierełło; Katarzyna Barczak; Iwona Poziomkowska-Gęsicka; Jerzy Wójcik; Dariusz Chlubek; Irena Baranowska-Bosiacka Journal: Int J Mol Sci Date: 2022-06-28 Impact factor: 6.208
Authors: Ruixue Hou; Lewis E Tomalin; Jessica Pintado Silva; Seunghee Kim-Schulze; Stephen S Whitehead; Ana Fernandez-Sesma; Anna P Durbin; Mayte Suárez-Fariñas Journal: JCI Insight Date: 2022-06-08
Authors: Luz M Medrano; Norma Rallón; Juan Berenguer; María A Jiménez-Sousa; Vicente Soriano; Teresa Aldámiz-Echevarria; Amanda Fernández-Rodríguez; Marcial García; Francisco Tejerina; Isidoro Martínez; José M Benito; Salvador Resino Journal: J Transl Med Date: 2016-09-02 Impact factor: 5.531
Authors: Nina F Øbro; Jacob Grinfeld; Miriam Belmonte; Melissa Irvine; Mairi S Shepherd; Tata Nageswara Rao; Axel Karow; Lisa M Riedel; Oliva B Harris; E Joanna Baxter; Jyoti Nangalia; Anna Godfrey; Claire N Harrison; Juan Li; Radek C Skoda; Peter J Campbell; Anthony R Green; David G Kent Journal: Hemasphere Date: 2020-05-21